Exelixis, Inc.: Exelixis and STORM Therapeutics Enter into Exclusive Collaboration and License Agreement to Discover and Develop Inhibitors of Novel RNA Modifying Enzymes

STORM to deliver small molecule ADAR1 clinical candidate compounds discovered using its proprietary RNA modifying enzyme drug discovery platform - Exelixis, Inc. (Nasdaq: EXEL) and STORM Therapeutics

Related Keywords

Cambridge ,Cambridgeshire ,United Kingdom ,Tony Kouzarides ,Eva Haas ,Varant Shirvanian ,Hal Mackins ,Keith Blundy ,Mary Clark ,Eric Miska ,Elakiya Rangarajah ,Peter Lamb ,Linkedin ,Daiichi Sankyo Company ,Twitter ,Taiho Ventures ,Nasdaq ,Exchange Commission ,University Of Cambridge ,Exelixis Inc ,Strategic Communications ,Ip Group ,Facebook ,Seroba Life Sciences ,Executive Vice President ,Scientific Strategy ,Chief Scientific Officer ,Chief Executive Officer ,Cancer Genome Atlas ,Professors Tony Kouzarides ,Cambridge Innovation Capital ,Pfizer Ventures ,Standard Poor ,Growing Companies ,Exelixi Quarterly Report ,Investors Contact ,Investor Relations Manager ,Media Contact ,Exelixis ,Storm ,Herapeutics ,Winter ,Exclusive ,Collaboration ,License ,Agreement ,Discover ,Evelop ,Inhibitors ,Novel ,Modifying ,Enzymes ,